Pantoprazole ameliorates liver fibrosis and suppresses hepatic stellate cell activation in bile duct ligation rats by promoting YAP degradation

Autor: He Hongwei, Na Zhang, Wei-xiao Niu, Xiu-Li Guo, Bao Yunyang, Mao-xu Ge, Yu Ren, Zhen-ning Lu

Publikováno v: Acta Pharmacol Sin

Liver fibrosis is one of the most severe pathologic consequences of chronic liver diseases, and effective therapeutic strategies are urgently needed. Proton pump inhibitors (PPIs) are H + /K + -ATPase inhibitors and currently used to treat acid-relat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::458131f9956c302ac08ee451dbaf386a
https://doi.org/10.1038/s41401-021-00754-w

A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters

Autor: Rong-Guang Shao, Dong-ke Yu, Maoxu Ge, Hong-Tao Liu, Juxian Wang, Wei-xiao Niu, Yi-xuan Zhang, Hongwei He, Shi-Ying Cai, Zhang Na, Ren Jinfeng, Yucheng Wang

Publikováno v: Acta Pharmacol Sin

The manipulation of bile acid (BA) homeostasis by blocking the ileal apical Na(+)-dependent bile salt transporter (ASBT/SLC10A2) may have therapeutic effects in nonalcoholic fatty liver disease. We developed a novel ASBT inhibitor, an N-(3,4-o-dichlo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86268f94b58c445699bd4ae7f3f82723
https://doi.org/10.1038/s41401-018-0195-3

Design, Synthesis, and Cytotoxic Activity of 3‐Aryl‐ N ‐hydroxy‐2‐(sulfonamido)propanamides in HepG2, HT‐1080, KB, and MCF‐7 Cells

Autor: Shao Duanyang, Guoning Zhang, Ziqiang Li, Wei-xiao Niu, Mei Zhu, Juxian Wang, Donghui Li, Yucheng Wang

Publikováno v: Chemistry & Biodiversity. 16

A new series of (sulfonamido)propanamides (6a1-6a13, 6b1-6b15, 7c1-7c5, 6d1-6d5, 6e1-6e6) was designed and synthesized. All the synthesized compounds were characterized by NMR and mass spectrometry. The target compounds were evaluated for their in vi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b84b8bc239499141106ea2a9946ae9
https://doi.org/10.1002/cbdv.201800646

Costunolide represses hepatic fibrosis through WW domain-containing protein 2-mediated Notch3 degradation.

Autor: Ge, Mao‐xu¹ (AUTHOR), Liu, Hong‐tao² (AUTHOR), Zhang, Na¹ (AUTHOR), Niu, Wei‐xiao¹ (AUTHOR), Lu, Zhen‐ning¹ (AUTHOR), Bao, Yun‐yang¹ (AUTHOR), Huang, Rui³ (AUTHOR), Yu, Dong‐ke⁴ (AUTHOR) kkygrace2411@yahoo.com, Shao, Rong‐guang¹ (AUTHOR) shaor@imb.pumc.edu.cn, He, Hong‐wei¹ (AUTHOR) hehwei@imb.pumc.edu.cn, Ge, Mao-Xu⁵ (AUTHOR), Liu, Hong-Tao⁶ (AUTHOR), Niu, Wei-Xiao⁵ (AUTHOR), Lu, Zhen-Ning⁵ (AUTHOR), Bao, Yun-Yang⁵ (AUTHOR), Yu, Dong-Ke⁷ (AUTHOR), Shao, Rong-Guang⁵ (AUTHOR), He, Hong-Wei⁵ (AUTHOR)

Publikováno v: British Journal of Pharmacology. Jan2020, Vol. 177 Issue 2, p372-387. 16p. 1 Color Photograph, 1 Chart, 9 Graphs.